Subscribe To
Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the […] The post Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis appeared first on ForexTV...
Read More
Posted: Mar 31 2023, 11:30
Author Name: forextv
Views: 110171